HDAC6 and COVID-19: Moreover, since the inflammation in COVID-19 patients is partially driven by NF-κB and characterized by increased TNF-α and IL-6 production (12), we investigated the global effect of the HDAC6 inhibitor ITF3756 on purified human monocytes stimulated with TNF-α.